Lipella pharmaceuticals to publish abstract detailing compelling preclinical support for new product candidate at asco 2024

Pittsburgh, april 05, 2024 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella,” “our”, “us” or the “company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has been accepted for the 2024 american society of clinical oncology (asco) meeting on may 31 through june 4 in chicago, illinois. lipella's abstract, “intravesical local administration of pembrolizumab for treatment of bladder cancer: a novel strategy to minimize toxicity” will be published at www.asco.org/abstracts.
LIPO Ratings Summary
LIPO Quant Ranking